A US-based KOL discusses the prostate cancer treatment algorithm with a focus on how PSMA-PET/CT has reshaped disease-state definitions across biochemical recurrence, non-metastatic castration-resistant and low volume metastatic disease. Positioning of androgen receptor pathway inhibitors, PARP inhibitors, taxanes and radioligand therapy is examined, together with payer behavior around labelled indications and views on pipeline therapies.

This interview was conducted on March 13, 2026. 

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.